Clinical Scorecard: FDA Expands Marstacimab Indication in Hemophilia A and B
At a Glance
| Category | Detail |
|---|---|
| Condition | Hemophilia A and B |
| Key Mechanisms | Targets the Kunitz 2 domain of tissue factor pathway inhibitor (TFPI) to restore balance between bleeding and coagulation. |
| Target Population | Patients aged 12 years and older with hemophilia A or B with inhibitors and pediatric patients aged 6 to 11 years with or without inhibitors. |
| Care Setting | Outpatient setting for routine prophylaxis. |
Key Highlights
- Marstacimab is the first subcutaneous non-factor therapy for pediatric patients with hemophilia B aged 6 to 11 years.
- Mean treated annualized bleeding rate (ABR) reduced by 93% compared to on-demand intravenous treatment.
- No routine treatment-related laboratory monitoring required.
- Dosing varies by age group: 150 mg loading dose for ages 6-11, 300 mg for ages 12-17.
- Common adverse reactions include injection-site reactions, headache, and pyrexia.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of hemophilia A or B confirmed through genetic testing and clinical evaluation.
Management
- Marstacimab administered once weekly by subcutaneous injection.
Monitoring & Follow-up
- No routine treatment-related laboratory monitoring required.
Risks
- Warnings for thromboembolic events, hypersensitivity reactions, embryofetal toxicity, and increased laboratory values of fibrin D-dimer and prothrombin fragment 1.2.
Patient & Prescribing Data
Adults and pediatric patients aged 6 years and older with hemophilia A or B.
Marstacimab significantly reduces bleeding rates in patients with hemophilia A or B.
Clinical Best Practices
- Consider patient age and inhibitor status when determining dosing.
- Monitor for adverse reactions post-injection.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
